首页 | 本学科首页   官方微博 | 高级检索  
     


DECLARE‐TIMI 58: Participants’ baseline characteristics
Authors:Itamar Raz MD  Marc P. Bonaca MD  Avivit Cahn MD  Eri T. Kato MD  Michael G. Silverman MD  Deepak L. Bhatt MD  Lawrence A. Leiter MD  Darren K. McGuire MD  John P. H. Wilding MD  Ingrid A. M. Gause‐Nilsson MD  Anna M. Langkilde MD  Peter A. Johansson MSc  Marc S. Sabatine MD  Stephen D. Wiviott MD
Affiliation:1. Diabetes Unit, Department of Internal Medicine, Hadassah Hebrew University Hospital, Jerusalem, IsraelI. R. and O. M. contributed equally.;2. TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts;3. Diabetes Unit, Department of Internal Medicine, Hadassah Hebrew University Hospital, Jerusalem, Israel;4. Kyoto University Hospital, Kyoto, Japan;5. Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada;6. University of Texas Southwestern Medical Center, Dallas, Texas;7. Obesity and Endocrinology Research Group, University of Liverpool, Liverpool, UK;8. AstraZeneca, Gothenburg, Sweden
Abstract:
Keywords:cardiovascular outcomes  CVOTs  dapagliflozin  SGLT2 inhibitors  type 2 diabetes
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号